Join Dana-Farber Cancer Institute for the 2nd International NUT Carcinoma Research Symposium, a timely meeting of clinical and translational oncology leaders. Sponsored by the NUT Carcinoma Alliance, this symposium aims to share critical research updates, develop consensus treatment guidelines, and set the national agenda for clinical trials, positioning NUT carcinoma research for its next breakthrough moment.
SYMPOSIUM AGENDA(Subject to Change)
8:00 AM. Breakfast and Registration8:30 AM. Introductory PresentationsWelcome and IntroductionJia Luo, MD, Dana-Farber Cancer Institute (DFCI)Christopher A. French, MD, Brigham and Women’s Hospital (BWH)Geoffrey Shapiro, MD, PhD, DFCI
Introduction to NUT Carcinoma: Background and Science – Christopher A. French, MD, BWH
Patient Perspective and Interview – Maddie Woepse, The Patrick Woepse Foundation
NUT Carcinoma Registry Update: Informing Clinical Care and Translational Research – Jia Luo, MD, DFCI
Next Generation Diagnostics in NC Diagnosis – John Iafrate, MD, PhD, MGH
9:35 AM. Break and Group Photo9:45 AM. Developing NUT Carcinoma Treatment Guidelines (Panel Discussion)Chairs: Jia Luo, MD, DFCI; Steven Dubois, MD, MS, DFCI; Benjamin H. Kann, MD, BWH; Hassan A. Khalil, MD, BWH; Michael Dennis, MD, DFCI
Thoracic Medical Oncology – Jia Luo, MD, DFCI; and Robert Hsu, MD, Keck School of Medicine at USC
Head and Neck Oncology – Michael Dennis, MD, DFCI
Pediatrics – Steven Dubois, MD, MS, DFCI and Boston Children’s Hospital; and Michael V. Ortiz, MD, MSKCC
Pathology – Lynette M. Sholl, MD, DFCI
Thoracic Surgery – Hassan A. Khalil, MD, BWH
ENT Surgery – Rosh K. Sethi, MD, MPH, DFCI
Thoracic Radiation Oncology – Benjamin H. Kann, MD, BWH
Investigational Cancer Therapeutics – Sarina A. Piha-Paul, MD Anderson Cancer Center at the University of Texas (MDACC)
ENT Radiation Oncology – Roy Tishler, DFCI
Nursing Professionals – Stephanie Canty, CNP, DFCI and Samantha Janell, BSN, RN, DFCI
11:15 AM. Future Directions Part OneChair: Kyle P. Eagen, PhD, Baylor College of Medicine
GENOME ORIGAMI: DNA Misfolding in NUT Carcinoma – Kyle P. Eagen, PhD, Baylor College of Medicine
BD2-selective inhibition is a unique vulnerability in NUT carcinoma – Christopher A. French, MD, BWH
Exploiting replicative stress in NUT carcinoma with ATR inhibition – Daryl Griffin, Laboratory of Geoffrey Shapiro, MD, PhD, DFCI
Transcriptional Chemical Inducers of Proximity (TCIPs) in NUT carcinoma – Hayden Malone, PhD, Laboratory of Jerry Crabtree, Stanford University
1:00 PM Lunch and Keynote AddressKeynote Speaker: George Demetri, DFCIIntroduced by Geoffrey Shapiro, MD, PhD, DFCI2:00 PM. Future Directions Part TwoChair: Hassan A. Khalil, MD, BWH
Tumor Microenvironment (TME) – James Brenner, DFCI
Immune Therapy/Cancer Vaccination – Derin Keskin, DFCI
PRAME and Other NC Epitopes – Alex Rubinsteyn, PhD, UNC School of Medicine
Antibody Drug Conjugates – Juyoung Choi, The Choi Lab at Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University; Laboratory of Molecular and Digital Pathology for Theranostics
3:40 PM. Break3:45 PM. Setting the Clinical Trials Agenda for NUT Carcinoma (Panel Discussion)Chairs: Michael Dennis, MD, DFCI; Geoffrey Shapiro, MD, PhD, DFCI
Lorraine Pelosof, MD, PhD, National Cancer Institute
Jia Luo, MD, DFCIGeoffrey Shapiro, MD, PhD, DFCI
Sarina A. Piha-Paul, MDACC
Jochen Lorch, MD, Northwestern Medicine
Kartik Sehgal, MD, DFCI
4:45 PM. Closing Remarks
Geoffrey Shapiro, MD, PhD, DFCI
Skip Victor, Patient Advocate
5:00 PM. Reception and Networking6:00 PM. End of Day
This event is sponsored by the NUT Carcinoma Alliance.
热门跟贴